Citations

Clear

3942 citation(s) found for "To, Van".

Scapular flap for maxillectomy defect reconstruction and preliminary results using three‐dimensional modeling
Modest, Mara C., Moore, Eric J. , Abel, Kathryn M. Van , Janus, Jeffrey R. , Sims, John R. , Olsen, Kerry D., Price, Daniel L. , Van Abel, Kathryn M

Mayo Clinic

The Laryngoscope | October 13, 2016 | Volume: 127 | Issue: 1 | Pages: No page available

10.1002/lary.26351 | PMID 27730644 Get It

Objectives/HypothesisDiscuss current techniques utilizing the scapular tip and subscapular system for free tissue reconstruction of maxillary defects and highlight the impact of medical modeling on these techniques with a case series.Study DesignCase review series at an academic hospital of patients undergoing maxillectomy + thoracodorsal scapula composite free flap (TSCF) reconstruction. Three‐dimensional (3D) models were used in the last five cases.Methods3D modeling, surgical, functional, and aesthetic outcomes were reviewed.ResultsNine patients underwent TSCF reconstruction for maxillectomy defects (median age = 43 years; range, 19–66 years). Five patients (55%) had a total maxillectomy (TM) ± orbital exenteration, whereas four patients (44%) underwent subtotal palatal maxillectomy. For TM, the contralateral scapula tip was positioned with its natural concavity recreating facial contour. The laterally based vascular pedicle was ideally positioned for facial vessel anastomosis. For subtotal‐palatal defect, an ipsilateral flap was harvested, but inset with the convex surface facing superiorly. Once 3D models were available from our anatomic modeling lab, they were used for intraoperative planning of the last five patients. Use of the model intraoperatively improved efficiency and allowed for better contouring/plating of the TSCF. At last follow‐up, all patients had good functional outcomes. Aesthetic outcomes were more successful in patients where 3D‐modeling was used (100% vs. 50%). There were no flap failures. Median follow‐up >1 month was 5.2 months (range, 1–32.7 months).ConclusionsReconstruction of maxillectomy defects is complex. Successful aesthetic and functional outcomes are critical to patient satisfaction. The TSCF is a versatile flap. Based on defect type, choosing laterality is crucial for proper vessel orientation and outcomes. The use of internally produced 3D models has helped refine intraoperative contouring and flap inset, leading to more successful outcomes.Level of Evidence4. Laryngoscope, 127:E8–E14, 2017
Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells
Taipaleenmäki, Hanna , Farina, Nicholas H. , Wijnen, André J. van , Stein, Janet L. , Hesse, Eric , Stein, Gary S., Lian, Jane B. , van Wijnen, Andre J, van Wijnen, Andre J

Mayo Clinic

Oncotarget | October 12, 2016 | Volume: 7 | Issue: 48 | Pages: 79032-79046

10.18632/oncotarget.12593 | PMID 27738322 Get It

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Beer, Tomasz M. , Kwon, Eugene D., Drake, Charles G. , Fizazi, Karim , Gravis, Gwénaëlle , Ganju, Vinod , Polikoff, Jonathan, Humanski, Piotr, Piulats, Josep M. , Mella, Pablo González, Ng, Siobhan, Jaeger, Dirk, Parnis, Francis, Franke, Fábio , Puente, Javier , Carvajal, Roman, Sengeløv, Lisa, McHenry, M. Brent , Varma, Arvind , Eertwegh, Alfonsus JM. van den, Gerritsen, Winald R. , Logothetis, Christopher, Saad, Fred, Gonzalez Mella, Pablo, Ng, Siobhan S, Parnis, Francis X, Franke, Fabio A, van den Eertwegh, Alfonsus J, Gerritsen, Winald, Logothetis, Christopher J. , Saad, Fred , Eertwegh, Alfonsus Johannes Maria van den, Gravis, Gwenaelle , Beer, Tomasz M

Mayo Clinic

Journal of Clinical Oncology | October 11, 2016 | Volume: 35 | Issue: 1 | Pages: 40-47

10.1200/jco.2016.69.1584 | PMID 28034081 Get It

Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Patients and Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) to ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Ipilimumab 10 mg/kg or placebo maintenance therapy was administered to nonprogressing patients every 3 months. The primary end point was overall survival (OS). Results Four hundred patients were randomly assigned to ipilimumab and 202 to placebo; 399 were treated with ipilimumab and 199 with placebo. Median OS was 28.7 months (95% CI, 24.5 to 32.5 months) in the ipilimumab arm versus 29.7 months (95% CI, 26.1 to 34.2 months) in the placebo arm (hazard ratio, 1.11; 95.87% CI, 0.88 to 1.39; P = .3667). Median progression-free survival was 5.6 months in the ipilimumab arm versus 3.8 with placebo arm (hazard ratio, 0.67; 95.87% CI, 0.55 to 0.81). Exploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab (23%) than with placebo (8%). Diarrhea (15%) was the only grade 3 to 4 treatment-related adverse event (AE) reported in ≥ 10% of ipilimumab-treated patients. Nine (2%) deaths occurred in the ipilimumab arm due to treatment-related AEs; no deaths occurred in the placebo arm. Immune-related grade 3 to 4 AEs occurred in 31% and 2% of patients, respectively. Conclusion Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer. The observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
Influence of menopause status and age on integrated central and peripheral hemodynamic responses to subsystolic cuffing during submaximal exercise
Iterson, Erik H. Van , Gramm, Courtney, Randall, Nicholas R. , Olson, Thomas P. , Van Iterson, Erik H, Van Iterson, Erik H

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | October 7, 2016 | Volume: 311 | Issue: 6 | Pages: H1382-H1391

10.1152/ajpheart.00310.2016 | PMID 27765745 Get It

Although pathophysiological links between postmenopause and healthy aging remain unclear, both factors are associated with increased blood pressure and sympathetic nerve activity (SNA) in women. Activation of polymodal musculoskeletal neural afferents originating within adventia of venules modulates SNA and blood pressure control during exercise in healthy adults. We hypothesized transient subsystolic regional circulatory occlusion (RCO) during exercise sensitizes these afferents leading to augmented systemic vascular resistance (SVR)-mediated increased mean arterial pressure (MAP) in postmenopause vs. premenopause. Normotensive women in premenopause or postmenopause ( n = 14 and 14; ages: 30 ± 9 and 55 ± 7 yr, respectively; P < 0.01) performed: 1) peak exercise testing and 2) fixed-load cycling at 30% peak workload (48 ± 11 and 38 ± 6 W, respectively; P < 0.01), whereby the initial 3 min were control exercise without RCO (CTL), thereafter including 2 min of bilateral-thigh RCO to 20, 40, 60, 80, or 100 mmHg (randomized), with 2 min deflation between RCO. Both MAP (17 ± 4 vs. 4 ± 4%, P = 0.02) and SVR (16 ± 8 vs. −3 ± 8%, P = 0.04) increased at 80 mmHg from CTL in postmenopause vs. premenopause, respectively. However, cardiac index was similar in postmenopause vs. premenopause at 80 mmHg from CTL (1 ± 6 vs. 7 ± 6%, respectively; P = 0.15). There was no continuous effect of aging in MAP ( P = 0.12), SVR ( P = 0.07), or cardiac index ( P = 0.18) models. These data suggest transient locomotor subsystolic RCO sensitizes musculoskeletal afferents, which provoke increased SVR to generate augmented MAP during exercise in postmenopause. These observations provide a novel approach for understanding the age-independent variability in exercise blood pressure control across the normotensive adult pre- to postmenopause spectrum.
Citrobacter koseri Pneumonia as Initial Presentation of Underlying Pulmonary Adenocarcinoma
Pennington, Kelly M. , Zyl, Martin van , Escalante, Patricio , Van Zyl, Martin

Mayo Clinic

Clinical Medicine Insights: Case Reports | October 6, 2016 | Volume: 9 | Issue: No issue available | Pages: No page available

10.4137/ccrep.s40616 | PMID 27746678 Get It

Citrobacter koseri is a motile, gram-negative rod traditionally known to cause infection in individuals with significant comorbidities and immunocompromised status. While most cases represent nosocomial infections, rarely community-acquired infections have been reported. We present a previously healthy man in his 60s with C. koseri pneumonia who was subsequently found to have underlying pulmonary adenocarcinoma, illustrating the need for further investigation for immunodeficiency and/or intrapulmonary pathology.
Prevalence and Surgical Implications of Dural Enhancement at the Porus Acusticus in Vestibular Schwannomas
Patel, Neil , Abel, Kathryn M. Van , Link, Michael J. , Driscoll, Colin L. W., Neff, Brian A., Lane, John I. , Carlson, Matthew L. , Van Abel, Kathryn M, Van Gompel, Jamie J, Gompel, Jamie J. Van , Van Abel, Kathryn M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 4, 2016 | Volume: 155 | Issue: 6 | Pages: 1021-1027

10.1177/0194599816670144 | PMID 27703093 Get It

ObjectiveDemonstrate the association of radiographic dural enhancement with increased tumor adherence at the porus acusticus, which may influence completeness of resection and facial nerve outcome.Study DesignCase series with chart review.SettingAcademic referral center.Subjects and MethodsA total of 205 consecutive patients with histopathologically confirmed vestibular schwannoma (VS) were evaluated. Patients with tumors exhibiting dural enhancement on postgadolinium T1‐weighted magnetic resonance imaging were identified and compared with matched controls. Completeness of resection, intraoperative details, and facial nerve outcomes were analyzed.ResultsExcluding strictly intracanalicular tumors (n = 32, 16%) and those with NF2 (n = 10, 4.9%), the presence of dural enhancement was radiographically confirmed in 16 (9.8%) cases. Paired analysis did not reveal significant baseline differences between cases and controls. Subtotal resection was performed in 5 (31%) of the 16 patients with tumors exhibiting dural enhancement, in contrast to 1 (3%) of the matched controls (P =. 01). Four (25%) demonstrated increased tumor adherence at the porus acusticus intraoperatively, compared with 1 control (3%, P =. 04). Long‐term facial nerve function was similar between cases and controls (81% vs 84% House‐Brackmann I‐II function, P = 1.00).ConclusionDural enhancement is present in approximately 10% of extracanalicular VS. Dural enhancement at the porus acusticus may represent hypervascularity, dural reaction, or infiltration, and portends increased tumor adherence and greater likelihood of subtotal resection to preserve facial nerve function. To our knowledge, this is the first series that reports the prevalence of this phenomenon in VS and the potential surgical implications. Recognition preoperatively may be valuable toward patient counseling.
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers
Wang, Zhaoming , Schumacher, Fredrick R. , Gayther, Simon A. , Casey, Graham , Sellers, Thomas A. , Gruber, Stephen B., Dunning, Alison M. , Michailidou, Kyriaki , Fachal, Laura , Doheny, Kimberly F. , Li, Yafang , Xiao, Xiangjun , Romm, Jane, Pugh, Elizabeth, Coetzee, Gerhard A. , Hazelett, Dennis J. , Bojesen, Stig E. , Caga-Anan, Charlisse , Haiman, Christopher A. , Kamal, Ahsan , Luccarini, Craig , Tessier, Daniel C., Vincent, Daniel , Bacot, François, Berg, David Van Den , Nelson, Stefanie A. , Demetriades, Stephen, Goldgar, David E., Forman, Judith L., Conti, David V. , Bickeböller, Heike , Risch, Angela , Waldenberger, Mélanie , Brüske‐Hohlfeld, Irene, Hicks, Belynda , McGuffog, Lesley, Kuchenbaecker, Karoline , Soucy, Penny, Manz, Judith, Cunningham, Julie M. , Butterbach, Katja, Kote‐Jarai, Zsofia , Kraft, Peter , Lindström, Sara , Adams, Marcia, McKay, James , Phelan, Catherine M., Benlloch, Sara, Kelemen, Linda E., Brennan, Paul , Riggan, Marjorie J. , O’Mara, Tracy A. , Shen, Hongbing , Shi, Yongyong , Thompson, Deborah J. , Goodman, Marc T. , Nielsen, Sune F. , LaBoissière, Sylvie, Schmit, Stephanie L. , Shelford, Tameka, Edlund, Christopher K., Taylor, Jack A. , Field, John K. , Park, Sue K. , Offit, Kenneth , Thomassen, Mads , Schmutzler, Rita K., Ottini, Laura , Hung, Rayjean J., Olama, Ali Amin Al , Peters, Ulrike , Eeles, Rosalind A. , Seldin, Michael F., Gillanders, Elizabeth M. , Seminara, Daniela, Antoniou, Antonis C. , Chenevix‐Trench, Georgia , Simard, Jacques , Easton, Douglas F. , Durocher, Francine , Hung, Rayjean J. , Amos, Christopher I. , Dennis, Joe , Byun, Jinyoung , Hunter, David J. , Spurdle, Amanda B. , Couch, Fergus J. , Giles, Graham G. , Ling, Hua , Lee, Andrew , FitzGerald, Liesel M. , Berchuck, Andrew , Marchini, Jonathan , Pharoah, Paul D.P. , Chanock, Stephen Jacob , Hazelett, Dennis J , Eeles, Rosalind A , Van Den Berg, David J , Hung, Rayjean J , Wang, Zhaoming , O'Mara, Tracy A , Field, John K , Dunning, Alison M , Michailidou, Kyriaki , Taylor, Jack A , Kraft, Peter , Simard, Jacques , Chenevix-Trench, Georgia , Ottini, Laura , Conti, David V , Bojesen, Stig E , Risch, Angela , Bickeböller, Heike , Shen, Hongbing , Goodman, Marc T , Fachal, Laura

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 3, 2016 | Volume: 26 | Issue: 1 | Pages: 126-135

10.1158/1055-9965.epi-16-0106 | PMID 27697780 Get It

Abstract Background: Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. Methods: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. Results: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. Conclusions: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. Impact: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126–35. ©2016 AACR.
Magnetic resonance imaging–guided laser interstitial thermal therapy for previously treated hypothalamic hamartomas
Burrows, Anthony M. , Marsh, W. Richard , Woodrum, David A. , Pollock, Bruce E. , Gorny, Krzysztof R. , Felmlee, Joel P. , Watson, Robert E. , Goerss, Steven, Worrell, Gregory A. , Kaufmann, Timothy J. , Goerss, S, Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | October 1, 2016 | Volume: 41 | Issue: 4 | Pages: E8

10.3171/2016.7.focus16218 | PMID 27690651 Get It

OBJECTIVE Hypothalamic hamartomas (HHs) are associated with gelastic seizures and the development of medically refractory epilepsy. Magnetic resonance imaging–guided laser interstitial thermal therapy (MRg-LITT) is a minimally invasive ablative treatment that may have applicability for these deep-seated lesions. Here, the authors describe 3 patients with refractory HHs who they treated with MRg-LITT. METHODS An institutional review board–approved prospective database of patients undergoing Visualase MRg-LITT was retrospectively reviewed. Demographic and historical medical data, including seizure and medication histories, previous surgeries, procedural details, and surgical complications, along with radiological interpretation of the HHs, were recorded. The primary outcome was seizure freedom, and secondary outcomes included medication reduction, seizure frequency, operative morbidity, and clinical outcome at the latest follow-up. RESULTS All 3 patients in the multi-institutional database had developed gelastic seizures related to HH at the ages of 7, 7, and 9 years. They presented for further treatment at 25, 28, and 48 years of age, after previous treatments with stereotactic radiosurgery in all cases and partial hamartoma resection in one case. One ablation was complicated by a small tract hemorrhage, which was stable on postoperative imaging. One patient developed hyponatremia and experienced weight gain, which were respectively managed with fluid restriction and counseling. At the most recent follow-up at a mean of 21 months (range 1–32 months), one patient was seizure free while another had meaningful seizure reduction. Medication was reduced in one case. CONCLUSIONS Adults with gelastic seizures despite previous treatments can undergo MRg-LITT with reasonable safety and efficacy. This novel therapy may provide a minimally invasive alternative for primary and recurrent HH as the technique is refined.
Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation
Jeganathan, Karthik B. , Limzerwala, Jazeel F. , Baker, Darren J. , Hamada, Masakazu , Nam, Hyun-Ja, Deursen, Willemijn H. van , Hamada, Naomi, Naylor, Ryan M. , Becker, Nicole A. , Davies, Brian A., Ree, Janine H. van, Mer, Georges , Maher, L. James, Katzmann, David J. , Deursen, Jan M. van , Kanakkanthara, Arun , van Deursen, Willemijn H, van Ree, Janine H, Shapiro, Virginia S, Hamada, Masakazu, Shapiro, Virginia Smith , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

Science | September 29, 2016 | Volume: 353 | Issue: 6307 | Pages: 1549-1552

10.1126/science.aaf7463 | PMID 27708105 Get It

Cyclin A2 activates the cyclin-dependent kinases Cdk1 and Cdk2 and is expressed at elevated levels from S phase until early mitosis. We found that mutant mice that cannot elevate cyclin A2 are chromosomally unstable and tumor-prone. Underlying the chromosomal instability is a failure to up-regulate the meiotic recombination 11 (Mre11) nuclease in S phase, which leads to impaired resolution of stalled replication forks, insufficient repair of double-stranded DNA breaks, and improper segregation of sister chromosomes. Unexpectedly, cyclin A2 controlled Mre11 abundance through a C-terminal RNA binding domain that selectively and directly binds Mre11 transcripts to mediate polysome loading and translation. These data reveal cyclin A2 as a mechanistically diverse regulator of DNA replication combining multifaceted kinase-dependent functions with a kinase-independent, RNA binding–dependent role that ensures adequate repair of common replication errors.